The human papillomavirus is the most common sexually transmitted infection. Nearly all sexually active people get it at some point in their lives. There are many types of HPV of which only some cause cancer, they are also known as high risk types. 99% of cervical cancers are caused by HPV infection. HPV testing is becoming a primary tool for the prevention of cervical cancer.
GENOMICA has been developing HPV genotyping kits for 25 years, always following the most recent international guidelines. The company uses its own technology, CLART®, with kits that detect up to 35 high and low risk types in a single assay. These kits are used internationally in various screening programs. At present the company is developing a new device for HPV genotyping, NEDxA, with unprecedented usability and speed of analysis.
In a world where personalized medicine is increasingly relevant, the detection of the HPV type can determine the treatment and improve the clinical outcome. The #theTypeMatters campaign aims to emphasize the importance of knowing the HPV type and raise the awareness about its life-saving potential.